Company intelligence / Profile preview
Magnaetus Therapeutics
- Ownership
- Private
- Development stage
- Preclinical
Overview
Magnaetus Therapeutics is developing a first-in-class peptide therapeutic designed to mimic the beneficial effects of exercise and calorie restriction. The therapy aims to reduce fat mass while preserving lean tissue, targeting obesity, metabolic syndrome, and age-related metabolic decline. The company’s approach is supported by over 15 years of academic research. No clinical trial results have been published yet; the program appears preclinical as of early 2025.
- Therapeutic areas
- Metabolic DisordersEndocrinology
- Modalities
- Peptide therapeutics (specifically, a peptide therapy based on an endogenous protein)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Magnaetus Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Magnaetus Therapeutics.